Podcast

Casting the Net: Precision Medicine for Greater Outreach and Better Outcomes in IBD

Launch Date
02/12/2025
Credit Amount
0.75
Credit Expires
02/12/2026
This activity is part of a series

Faculty

Amar Naik, MD
Moderator
Director of Inflammatory Bowel Disease Program
Founding Partner, Midwest Digestive Health & Nutrition
Des Plaines, IL
Neilanjan Nandi, MD, FACG, AGAF, FACP
Associate Professor of Clinical Medicine
Division of Gastroenterology & Hepatology
The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Penn Presbyterian Medical Center, University of Pennsylvania
Philadelphia, PA
Neilanjan Nandi, MD, FACG, AGAF, FACP

Neilanjan Nandi, FACG, AGAF, FACP, is Associate Professor of Clinical Medicine at Penn Presbyterian Medical Center at the University of Pennsylvania. Dr. Nandi’s practice focuses on the management of inflammatory bowel disease (IBD) (e.g., Crohn’s disease, ulcerative colitis) and recurrent Clostridium difficile (C. difficile) infection via fecal microbiota transplantation (FMT). Dr. Nandi serves on the executive council of the Philadelphia Crohn’s & Colitis Foundation (CCF) and on the medical advisory board of the United Ostomy Associates of America (UOAA), coordinates outreach on the American College of Gastroenterology Patient Care Committee, and is a founding board member of the South Asian IBD Alliance (SAIA). He also regularly peer reviews research publications and serves on the social media editorial board for the premier journals Inflammatory Bowel Diseases and Crohn’s & Colitis 360. His research has focused on studying conditions co-morbid to IBD quality of care, namely the diagnosis and management of refractory C. difficile infection and the application of FMT in C. difficile; also, characterizing the management and consequences of iron deficiency anemia and non-alcoholic fatty liver disease in patients with IBD. Dr. Nandi has authored numerous book chapters on the diagnosis and management of various viral, parasitic, mycobacterial, and bacterial infections of the gastrointestinal (GI) tract.

Dr. Nandi’s fervor for clinical education has been recognized with multiple teaching awards. He was honored as the 2019 Physician Hero by the Philadelphia/Delaware Valley Crohn’s and Colitis Foundation at their annual Take Steps for Crohn’s & Colitis event, and wields digital and social media platforms to amplify education, outreach, and advocacy in IBD to clinicians and patients. He was also awarded the Philadelphia CCF’s Chairman’s Citation in 2022. He is the regular host of the academic podcast GI Insights: IBD Crosstalk, which features high-yield, evidence-based medicine discussions with guests from different interdisciplinary fields critical to providing comprehensive IBD care. Dr. Nandi’s passions include fitness, cooking, virtual reality gaming, reading, and dancing. Follow him on social @fitwitmd.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration

Statement of Need

The role of precision medicine in the treatment of IBD has been increasingly recognized as essential for improving patient outcomes. Precision medicine aims to tailor therapeutic approaches based on individual patient characteristics, including genetic, molecular, and environmental factors. This personalized strategy allows for more accurate prediction of disease course, therapeutic response, and the identification of optimal treatment regimens. Recent advances in genomics and molecular biology have also facilitated the identification of numerous genetic variants associated with IBD. Despite the importance of precision medicine in IBD clinicians struggle with identifying which clinical and biological factors provide the greatest utility in predicting disease course and assessing clinical outcomes over time as well as translating the science into clinical care.

In this third installment of a CMEO podcast series expert faculty will discuss strategies to better apply precision medicine to emerging IBD therapies such as TL1A inhibitors as a means of closing gaps in care.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Apply precision medicine to emerging IBD therapies such as TL1A inhibitors as a means of closing gaps in care

Financial Support

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Target Audience

Gastroenterologists, IBD specialists, specialty nurse practitioners (NPs) and physician associates (PAs), nurses, and pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 0.75

CME Outfitters, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists (ACPE) 0.75

This application-based activity is approved for 0.75 contact hours (0.075 CEUs) of continuing pharmacy credit (JA0007185-0000-25-033-H01-P).

Nurses (ANCC) 0.75

This activity is designated for 0.75 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology. 

Physician Assistants (AAPA): 0.75

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 02/12/26. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.75

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Faculty

Dr. Naik reports the following financial relationships:

Consultant: AbbVie Inc.; Bristol Myers Squibb Company; Eli Lilly & Company; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Speakers Bureau: AbbVie Inc.; Bristol Myers Squibb Company; Eli Lilly & Company; and Takeda Pharmaceuticals U.S.A., Inc.

Dr. Nandi reports the following financial relationships:

Consultant: AbbVie Inc.; Boehringer-Ingelheim; Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc.; and Pfizer Inc.

Planners

Ms. Aswani-Omprakash reports the following financial relationships:

Advisory Board: Ardelyx; Genentech-Roche; Johnson & Johnson; Parexel; Pfizer Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Tillotts AG

Consultant: AbbVie Inc.; Boehringer Ingelheim; Convatec; Genentech, Inc./Roche; Hollister, Inc.; Johnson & Johnson; Parexel; Walgreens

Speakers Bureau: AbbVie; Boehringer Ingelheim; Genentech, Inc./Roche; Iterative Health; Hollister, Inc.; Johnson & Johnson; Parexel; Takeda Pharmaceuticals U.S.A., Inc.

Employment: Senior Director of Strategic Partnerships at Sommer Consulting

Ms. Collins reports the following financial relationships:

Advisory Board and Consultant: AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Speakers Bureau: AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Lilly and Takeda Pharmaceuticals U.S.A., Inc.

The following individuals have no financial relationships to disclose: 

Rebecca Vargas-Jackson, MD  (Peer Reviewer)
Jessica Giddens, DNP, APRN, FPMHNP-BC, RN-BC (Peer Reviewer)
Evan Luberger (Planning Committee)
Sireesha Murala, MD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

PD-116-021225-44

Casting the Net: Precision Medicine for Greater Outreach and Better Outcomes in IBD
Event Date: 02/12/2025
Register

Activities in the Series

02/12/2025

Precision Rules in Medicine: The Evidence Propelling IBD Treatments to Hit the Target

0.75
Begin Learn More
Gastroenterology
02/12/2025

Closing Gaps in Care: Re-framing Treatment Approaches from Reactive to Proactive in IBD

0.75
Begin Learn More